First patient dosed in Phase 1/2a study with novel immune rejuvenator, a trispecific antibody-fusion protein Two MDX2004 abstracts accepted for ...

Abstracts and additional details can be found at the CNS Summit 2025 website.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical-stage oncology company developing anchored immunotherapies to improve the therapeutic window for immuno-oncology drugs, announced ...

Phase 1 data of first-in-class NBD1 stabilizers, SION-719 and SION-451, demonstrated they were generally well tolerated and ...

Autolus Therapeutics (AUTL) announces that follow-up data from the ongoing CARLYSLE trial, a Phase 1 dose confirmation clinical trial of obe-cel ...

Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) announced that its first-in-class idiopathic pulmonary ...

Circle Pharma, a clinical-stage biopharmaceutical company advancing macrocycle therapeutics for difficult-to-treat cancers, today announced that its Trials in Progress abstract has been selected for ...

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. (“OncoNano”), a clinical-stage biotechnology company pioneering the development of polymeric micelles encapsulating anti-cancer payloads, ...

MAIA Biotechnology (MAIA) announced highlights from a recent presentation at the European Society for Medical Oncology, ESMO, Congress 2025 held ...

Data contribute to growing body of support around the anti-fibrotic activity of EFX in patients with pre-cirrhotic MASH SOUTH SAN FRANCISCO, Calif., May 10, 2025 (GLOBE NEWSWIRE) -- Akero Therapeutics ...

Refractory chronic cough is a condition with high unmet need and no FDA-approved therapies. RCC is defined as a persistent cough lasting >8 weeks despite treatment for an underlying condition (i.e., ...

Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, ...